The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma: A preliminary report

Michael W. Method, Aldo N Serafini, Hervy E. Averette, Michael Rodriguez, Manuel A. Penalver, Bernd Uwe Sevin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND. Accurate evaluation of patients with ovarian carcinoma who have completed primary therapy often requires surgical exploration. Radioimmunoscintigraphy (RIS) represents an evolving technique that may allow noninvasive detection and localization of persistent or recurrent disease in these patients. METHODS. Our prospective, blinded study enrolled patients with normal CA 125 levels and no clinical evidence of disease after primary cytoreductive surgery and cytotoxic chemotherapy for ovarian carcinoma. Each patient underwent RIS using 111Indium-satumomab pendetide (labeled antibody B72.3 to the tumor-associated antigen TAG-72) and abdominal/pelvic computed tomography (CT) prior to reassessment laparotomy. RESULTS. Twenty patients were enrolled from January 1994 to January 1995. Two patients with negative RIS scans refused reassessment laparotomy and were with out evidence of disease >15 months from the study. Twelve of the remaining 18 patients (66.7%) had histologically proven disease at reassessment laparotomy, RIS images indicated the presence of disease in all 12 patients, whereas CT scans detected disease in only 2 patients. In three of five patients, biopsy- proven microscopic disease (no gross disease at the time of laparotomy) was found only in specimens obtained by RIS-directed biopsies. RIS was superior to CT in sensitivity (100% vs. 16.7%), accuracy (72% vs. 33%), and negative predictive value (100% vs. 28.6%) (P < 0.005). CONCLUSIONS. Routine use of CT is of limited value in the assessment of ovarian carcinoma patients with negative physical examinations and normal CA 125 levels. With its high level of sensitivity and negative predictive value, RIS may play a role in the detection of persistent disease in this population and aid in the classification of patients into three distinct groups: those with gross residual disease, small volume or microscopic disease, and no disease. Separation of this heterogenous group without surgery may help guide subsequent consolidation therapy. However, attaining a high level accuracy with RIS, depends on optimizing the method of image acquisition, the timing of scans, and the reconstruction of data.

Original languageEnglish
Pages (from-to)2286-2293
Number of pages8
JournalCancer
Volume77
Issue number11
DOIs
StatePublished - Jun 1 1996

Fingerprint

Radioimmunodetection
Laparotomy
Tomography
Carcinoma
Biopsy
Physical Examination

Keywords

  • computed tomography
  • monoclonal antibodies
  • ovarian carcinoma
  • radioimmunoscintigraphy
  • reassessment laparotomy
  • second-look laparotomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma : A preliminary report. / Method, Michael W.; Serafini, Aldo N; Averette, Hervy E.; Rodriguez, Michael; Penalver, Manuel A.; Sevin, Bernd Uwe.

In: Cancer, Vol. 77, No. 11, 01.06.1996, p. 2286-2293.

Research output: Contribution to journalArticle

Method, Michael W. ; Serafini, Aldo N ; Averette, Hervy E. ; Rodriguez, Michael ; Penalver, Manuel A. ; Sevin, Bernd Uwe. / The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma : A preliminary report. In: Cancer. 1996 ; Vol. 77, No. 11. pp. 2286-2293.
@article{852264fb008941ff96ab7786726ce866,
title = "The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma: A preliminary report",
abstract = "BACKGROUND. Accurate evaluation of patients with ovarian carcinoma who have completed primary therapy often requires surgical exploration. Radioimmunoscintigraphy (RIS) represents an evolving technique that may allow noninvasive detection and localization of persistent or recurrent disease in these patients. METHODS. Our prospective, blinded study enrolled patients with normal CA 125 levels and no clinical evidence of disease after primary cytoreductive surgery and cytotoxic chemotherapy for ovarian carcinoma. Each patient underwent RIS using 111Indium-satumomab pendetide (labeled antibody B72.3 to the tumor-associated antigen TAG-72) and abdominal/pelvic computed tomography (CT) prior to reassessment laparotomy. RESULTS. Twenty patients were enrolled from January 1994 to January 1995. Two patients with negative RIS scans refused reassessment laparotomy and were with out evidence of disease >15 months from the study. Twelve of the remaining 18 patients (66.7{\%}) had histologically proven disease at reassessment laparotomy, RIS images indicated the presence of disease in all 12 patients, whereas CT scans detected disease in only 2 patients. In three of five patients, biopsy- proven microscopic disease (no gross disease at the time of laparotomy) was found only in specimens obtained by RIS-directed biopsies. RIS was superior to CT in sensitivity (100{\%} vs. 16.7{\%}), accuracy (72{\%} vs. 33{\%}), and negative predictive value (100{\%} vs. 28.6{\%}) (P < 0.005). CONCLUSIONS. Routine use of CT is of limited value in the assessment of ovarian carcinoma patients with negative physical examinations and normal CA 125 levels. With its high level of sensitivity and negative predictive value, RIS may play a role in the detection of persistent disease in this population and aid in the classification of patients into three distinct groups: those with gross residual disease, small volume or microscopic disease, and no disease. Separation of this heterogenous group without surgery may help guide subsequent consolidation therapy. However, attaining a high level accuracy with RIS, depends on optimizing the method of image acquisition, the timing of scans, and the reconstruction of data.",
keywords = "computed tomography, monoclonal antibodies, ovarian carcinoma, radioimmunoscintigraphy, reassessment laparotomy, second-look laparotomy",
author = "Method, {Michael W.} and Serafini, {Aldo N} and Averette, {Hervy E.} and Michael Rodriguez and Penalver, {Manuel A.} and Sevin, {Bernd Uwe}",
year = "1996",
month = "6",
day = "1",
doi = "10.1002/(SICI)1097-0142(19960601)77:11<2286::AID-CNCR16>3.0.CO;2-T",
language = "English",
volume = "77",
pages = "2286--2293",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma

T2 - A preliminary report

AU - Method, Michael W.

AU - Serafini, Aldo N

AU - Averette, Hervy E.

AU - Rodriguez, Michael

AU - Penalver, Manuel A.

AU - Sevin, Bernd Uwe

PY - 1996/6/1

Y1 - 1996/6/1

N2 - BACKGROUND. Accurate evaluation of patients with ovarian carcinoma who have completed primary therapy often requires surgical exploration. Radioimmunoscintigraphy (RIS) represents an evolving technique that may allow noninvasive detection and localization of persistent or recurrent disease in these patients. METHODS. Our prospective, blinded study enrolled patients with normal CA 125 levels and no clinical evidence of disease after primary cytoreductive surgery and cytotoxic chemotherapy for ovarian carcinoma. Each patient underwent RIS using 111Indium-satumomab pendetide (labeled antibody B72.3 to the tumor-associated antigen TAG-72) and abdominal/pelvic computed tomography (CT) prior to reassessment laparotomy. RESULTS. Twenty patients were enrolled from January 1994 to January 1995. Two patients with negative RIS scans refused reassessment laparotomy and were with out evidence of disease >15 months from the study. Twelve of the remaining 18 patients (66.7%) had histologically proven disease at reassessment laparotomy, RIS images indicated the presence of disease in all 12 patients, whereas CT scans detected disease in only 2 patients. In three of five patients, biopsy- proven microscopic disease (no gross disease at the time of laparotomy) was found only in specimens obtained by RIS-directed biopsies. RIS was superior to CT in sensitivity (100% vs. 16.7%), accuracy (72% vs. 33%), and negative predictive value (100% vs. 28.6%) (P < 0.005). CONCLUSIONS. Routine use of CT is of limited value in the assessment of ovarian carcinoma patients with negative physical examinations and normal CA 125 levels. With its high level of sensitivity and negative predictive value, RIS may play a role in the detection of persistent disease in this population and aid in the classification of patients into three distinct groups: those with gross residual disease, small volume or microscopic disease, and no disease. Separation of this heterogenous group without surgery may help guide subsequent consolidation therapy. However, attaining a high level accuracy with RIS, depends on optimizing the method of image acquisition, the timing of scans, and the reconstruction of data.

AB - BACKGROUND. Accurate evaluation of patients with ovarian carcinoma who have completed primary therapy often requires surgical exploration. Radioimmunoscintigraphy (RIS) represents an evolving technique that may allow noninvasive detection and localization of persistent or recurrent disease in these patients. METHODS. Our prospective, blinded study enrolled patients with normal CA 125 levels and no clinical evidence of disease after primary cytoreductive surgery and cytotoxic chemotherapy for ovarian carcinoma. Each patient underwent RIS using 111Indium-satumomab pendetide (labeled antibody B72.3 to the tumor-associated antigen TAG-72) and abdominal/pelvic computed tomography (CT) prior to reassessment laparotomy. RESULTS. Twenty patients were enrolled from January 1994 to January 1995. Two patients with negative RIS scans refused reassessment laparotomy and were with out evidence of disease >15 months from the study. Twelve of the remaining 18 patients (66.7%) had histologically proven disease at reassessment laparotomy, RIS images indicated the presence of disease in all 12 patients, whereas CT scans detected disease in only 2 patients. In three of five patients, biopsy- proven microscopic disease (no gross disease at the time of laparotomy) was found only in specimens obtained by RIS-directed biopsies. RIS was superior to CT in sensitivity (100% vs. 16.7%), accuracy (72% vs. 33%), and negative predictive value (100% vs. 28.6%) (P < 0.005). CONCLUSIONS. Routine use of CT is of limited value in the assessment of ovarian carcinoma patients with negative physical examinations and normal CA 125 levels. With its high level of sensitivity and negative predictive value, RIS may play a role in the detection of persistent disease in this population and aid in the classification of patients into three distinct groups: those with gross residual disease, small volume or microscopic disease, and no disease. Separation of this heterogenous group without surgery may help guide subsequent consolidation therapy. However, attaining a high level accuracy with RIS, depends on optimizing the method of image acquisition, the timing of scans, and the reconstruction of data.

KW - computed tomography

KW - monoclonal antibodies

KW - ovarian carcinoma

KW - radioimmunoscintigraphy

KW - reassessment laparotomy

KW - second-look laparotomy

UR - http://www.scopus.com/inward/record.url?scp=0029884128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029884128&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960601)77:11<2286::AID-CNCR16>3.0.CO;2-T

DO - 10.1002/(SICI)1097-0142(19960601)77:11<2286::AID-CNCR16>3.0.CO;2-T

M3 - Article

C2 - 8635097

AN - SCOPUS:0029884128

VL - 77

SP - 2286

EP - 2293

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -